Biotech Values

[DewDiligence]

GILD—We now know that Stifel was indeed out to lunch (as noted in #msg-101431769) when they projected that 90% of Solavdi + Ledipasvir patients would take the 8w regimen. According to John Milligan on the MS webcast yesterday, GILD expects 45% of patients will take the 8w regimen and 55% will take the 12w regimen.

Some sell-side analysts really don’t have a clue in the HCV arena.